In a new report funded by AstraZeneca, authors St. Jean et al. take a global perspective and note that in some cases regulatory approval, in other cases reimbursement approval, lag for the diagnostics that drive precision medicine. They suggest some paths forward based on a comparison of countries and stakeholders and emphasize the need for collaboration. See the article here.
